The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells

Molecular and Cellular Endocrinology

Volumn 315, Issue 1-2, 2010, Pages 87-94

  Grozinsky Glasberg, Simona ^a,b   Rubinfeld, Hadara ^a,b   Nordenberg, Yardena ^a,b   Gorshtein, Alexander ^a,b   Praiss, Michal ^a,b   Kendler, Efrat ^a,b   Feinmesser, Rafael ^a,b   Grossman, Ashley B ^c   Shimon, Ilan ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Akt mTOR p70S6 pathway; Antiproliferation; MTC; RAD001

Indexed keywords

CALCITONIN; CARCINOEMBRYONIC ANTIGEN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; S6 KINASE;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CASE REPORT; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME PHOSPHORYLATION; HORMONE RELEASE; HUMAN; HUMAN CELL; MALE; MITOSIS INHIBITION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA;

AGED; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CELL CYCLE; CELL SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; THYROID GLAND; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 71849090738     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.09.027     Document Type: Article

References (36)

1. Altomare D.A., and Testa J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 24 (2005) 7455-7464
2. Bellacosa A., de Feo D., Godwin A.K., Bell D.W., Cheng J.Q., Altomare D.A., Wan M., Dubeau L., Scambia G., Masciullo V., Ferrandina G., Benedetti P.P., Mancuso S., Neri G., and Testa J.R. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64 (1995) 280-285
3. Brierley J.D., and Tsang R.W. External beam radiation therapy for thyroid cancer. Endocrinol. Metab. Clin. North Am. 37 (2008) 497-509
4. Cakir M., and Grossman A.B. Medullary thyroid cancer: molecular biology and novel molecular therapies. Neuroendocrinology (2009) 10.1159/000220827
5. Chiang G.G., and Abraham R.T. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J. Biol. Chem. 280 27 (2005) 25485-25490
6. Eriksson B., Renstrup J., Imam H., and Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann. Oncol. 8 (1997) 1041-1044
7. Fagin J.A. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J. Endocrinol. 183 (2004) 249-256
8. Fromigue J., De Baere T., Baudin E., Dromain C., Leboulleux S., and Schlumberger M. Chemoembolization for liver metastases from medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 91 (2006) 2496-2499
9. Grozinsky-Glasberg S., Franchi G., Teng M., Leontiou C.A., Ribeiro de Oliveira Jr. A., Dalino P., Salahuddin N., Korbonits M., and Grossman A.B. Octreotide and the mTOR inhibitor RAD001 (Everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 87 (2008) 168-181
10. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C.J., Zuelke C., Farkas S., Anthuber M., Jauch K.W., and Geissler E.K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8 (2002) 128-135
11. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 18 (2004) 1926-1945
12. Khoo S.K., Warner N.L., Lie J.T., and Mackay I.R. Carcinoembryonic antigenic activity of tissue extracts: a quantitative study of malignant and benign neoplasms, cirrhotic liver, normal adult and fetal organs. Int. J. Cancer 11 (1973) 681-687
13. Kirchner G.I., Meier-Wiedenbach I., and Manns M.P. Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet. 43 (2004) 83-95
14. Kunnimalaiyaan M., Ndiaye M., and Chen H. Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery 140 (2006) 1009-1014
15. Laure G.A., Al Ghulzan A., Auperin A., Leboulleux S., Chehboun A., Troalen F., Dromain C., Lumbroso J., Baudin E., and Schlumberger M. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur. J. Endocrinol. 158 (2008) 239-246
16. Leboulleux S., Baudin E., Travagli J.P., and Schlumberger M. Medullary thyroid carcinoma. Clin. Endocrinol. (Oxf.) 61 (2004) 299-310
17. Li B., Sun A., Youn H., Hong Y., Terranova P.F., Thrasher J.B., Xu P., and Spencer D. Conditional Akt activation promotes androgen-independent progression of prostate cancer. Carcinogenesis 28 (2007) 572-583
18. Miles L.E.M., Lipschitz D.A., Bieber C.P., and Cook J.D. Measurement of serum ferritin by a 2-site immunoradiometric assay. Anal. Biochem. 61 (1974) 209-224
19. Moreno A., Akcakanat A., Munsell M.F., Soni A., Yao J.C., and Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr. Relat. Cancer 15 (2008) 257-266
20. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., Grunwald V., Thompson J.A., Figlin R.A., Hollaender N., Urbanowitz G., Berg W.J., Kay A., Lebwohl D., and Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 (2008) 449-456
21. Nocera M., Baudin E., Pellegriti G., Cailleux A.F., Mechelany-Corone C., and Schlumberger M. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br. J. Cancer 83 (2000) 715-718
22. Oberg K. Management of neuroendocrine tumours. Ann. Oncol. 15 Suppl. 4 (2004) iv293-iv298
23. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., and Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66 (2006) 1500-1508
24. Rosen N., and She Q.B. Akt and cancer-is it all mTOR?. Cancer Cell 10 (2006) 254-256
25. Rubinfeld H., Hadani M., Barkai G., Taylor J.E., Culler M.D., and Shimon I. Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas. J. Clin. Endocrinol. Metab. 91 (2006) 2257-2263
26. Schlumberger M., Carlomagno F., Baudin E., Bidart J.M., and Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat. Clin. Pract. Endocrinol. Metab. 4 (2008) 22-32
27. Schlumberger M., Abdelmoumene N., Delisle M.J., and Couette J.E. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br. J. Cancer 71 (1995) 363-365
28. Scollo C., Baudin E., Travagli J.P., Caillou B., Bellon N., Leboulleux S., and Schlumberger M. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J. Clin. Endocrinol. Metab. 88 (2003) 2070-2075
29. Shaha A.R., Ferlito A., and Rinaldo A. Distant metastases from thyroid and parathyroid cancer. ORL J. Otorhinolaryngol. Relat. Spec. 63 (2001) 243-249
30. Sippel R.S., Kunnimalaiyaan M., and Chen H. Current management of medullary thyroid cancer. Oncologist 13 (2008) 539-547
31. Tamburini J., Elie C., Bardet V., Chapuis N., Park S., Broet P., Cornillet-Lefebvre P., Lioure B., Ugo V., Blanchet O., Ifrah N., Witz F., Dreyfus F., Mayeux P., Lacombe C., and Bouscary D. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 110 (2007) 1025-1028
32. Vignot S., Faivre S., Aguirre D., and Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 16 (2005) 525-537
33. Wang L., Ignat A., and Axiotis C.A. Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl. Immunohistochem. Mol. Morphol. 10 (2002) 139-146
34. Yao J.C., Phan A., Chang D.Z., Wolff R.A., Jacobs C., Mares J.E., Gupta S., Meric-Bernstam F., and Rashid A. Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGNET). ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25 18S (June 20 Supplement) (2007) 4503
35. Zitzmann K., De Toni E.N., Brand S., Goke B., Meinecke J., Spottl G., Meyer H.H., and Auernhammer C.J. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 85 (2007) 54-60
36. Zitzmann K., Vlotides G., Goke B., and Auernhammer C.J. PI (3) K-Akt-mTOR pathway as a potential therapeutic target in neuroendocrine tumors. Exp. Rev. Endocrinol. Metabol. (2008) 207-222